Johnson & Johnson has raised its annual dividend for more than 60 consecutive years. That puts it among the most elite group of income stocks in existence — a company that kept raising its payout through the Tylenol poisoning scare of 1982, the opioid litigation that resulted in billions in settlements, multiple patent cliffs on blockbuster drugs, and the 2023 spinoff of its consumer health division into a separate company called Kenvue.
Most companies would have cut the dividend through any one of those events. JNJ cut through none of them.
What the Streak Covers
The 60+ year streak is worth examining not just as a number but as a stress test. The years it covers include:
- 1982: The Tylenol crisis. Someone laced bottles with cyanide in Chicago, killing seven people. JNJ voluntarily recalled 31 million bottles at a cost of $100 million and faced existential brand risk. It raised its dividend that year.
- 2009: The financial crisis. JNJ's diversified model — pharmaceuticals, medical devices, and consumer health — proved its value. While financials were in freefall, JNJ's cash flows held steady.
- 2020: COVID. JNJ's pharmaceutical division was developing a COVID vaccine (eventual revenue), while its consumer health and device businesses faced supply chain disruption. Dividend raised.
- 2023: JNJ spun off its consumer health division (Band-Aid, Neutrogena, Tylenol) as Kenvue. The restructuring kept the dividend intact.
Each of these events would have given management cover to pause or cut. None resulted in a cut. That consistency reflects something structural about the business — specifically, the diversification of its cash flows across multiple large healthcare segments, each with independent revenue drivers.
The Pharmaceutical Moat Problem — and Why JNJ Survives It
Pharmaceutical companies face a recurring structural threat: patent expiration. When a blockbuster drug loses exclusivity, generic manufacturers enter the market and prices collapse, often reducing revenue on that drug by 80-90% within two years.
This creates a treadmill problem — the company must constantly replenish its drug pipeline to replace revenue from drugs going off-patent. Many pharma companies fail to keep pace and see earnings deteriorate badly.
JNJ manages this risk through scale and diversification. Its pharmaceutical segment alone generates over $50 billion in annual revenue with a pipeline that spans oncology (Darzalex, Tecvayli), immunology (Stelara, Tremfya), and neuroscience (Spravato). When one drug faces a patent cliff, the revenue decline is cushioned by growth in other franchise areas.
The medical device segment — MedTech — provides additional insulation. Surgical robotics (Ottava, in development), orthopedics, and cardiovascular devices don't face the same patent-cliff dynamics as drugs. Revenue is more cyclical (tied to elective procedure volumes) but less subject to sudden competitive compression.
Reading the Yield Chart
JNJ's yield history over the past decade has oscillated in a relatively tight range — typically between approximately 2.2% and 3.5%. This range reflects a blue-chip quality business: not high enough yield to attract yield-trap hunters, not low enough to signal overvaluation at most prices.
The Weiss undervalue threshold has historically corresponded to the upper portion of this range — when the stock price falls enough relative to the dividend that income investors start finding it compelling versus alternatives. The overvalue zone has corresponded to periods when the market priced JNJ's defensive qualities at a premium: low rates driving capital into quality dividend payers, or uncertainty driving flight to perceived safety.
After the Kenvue spinoff in 2023, JNJ's yield range reset somewhat because the company's dividend was adjusted to reflect the reduced scale of the remaining business. For Weiss analysis, the post-spinoff yield history is the more relevant reference — the pre-spinoff data reflects a structurally different company.
The Litigation Overhang
JNJ carries significant legal risk that income investors should understand clearly. The company faces tens of billions in talc-related lawsuits (alleged link between baby powder and ovarian cancer), opioid settlements, and ongoing device litigation.
JNJ has attempted multiple times to use the Texas Two-Step bankruptcy strategy — isolating the talc liability in a subsidiary and pushing it into bankruptcy — to resolve these claims at a discount. Courts have pushed back on this approach. The liability remains unresolved and represents a genuine financial risk, though the company's balance sheet ($20+ billion in cash, AAA credit rating) provides substantial capacity to absorb settlements.
The practical implication for income investors: JNJ's dividend appears well-covered by operating cash flows regardless of litigation outcomes within any reasonable range. An extreme adverse outcome would be painful but probably not dividend-threatening given the company's financial strength. This is one reason the market continues to assign JNJ a relatively low yield despite the headline litigation risk.
Payout Metrics
JNJ's earnings payout ratio typically runs 40–55% — modest for a company of this quality, reflecting healthy earnings per share relative to the dividend. The free cash flow payout is similarly conservative. This coverage provides substantial buffer: even in a year with significant litigation charges or drug revenue declines, the dividend does not approach the edge of sustainability.
The dividend growth rate has been consistent at roughly 5–7% annually. This is not aggressive compounding, but it's meaningfully above inflation and has been sustained for six decades.
What JNJ Is Good For
JNJ belongs in an income portfolio as a core defensive holding — a position that holds its value in downturns, maintains the dividend through crises, and provides slow but reliable income growth. It's not a high-yield stock (current yield typically 2.5–3.5%), and it's not a high-growth stock. It is one of the highest-quality dividend payers in the market by almost any measure.
The right time to add to JNJ, by the Weiss framework, is when the yield is near the top of its post-spinoff historical range — which has typically coincided with periods of market stress, litigation headlines, or sector-wide rotation away from healthcare. Those moments of fear tend to be the best entry points for a business this structurally durable.
Track JNJ's Weiss valuation signal and yield history on DividendVisual. View the JNJ analysis →